Bramante Biologics
An AI-native CDMO building modular microfactories to manufacture protein therapeutics faster and domestically in the US, targeting the wave of AI-designed biologics and the reshoring of drug manufacturing away from China.
Bramante Biologics
An AI-native CDMO building modular microfactories to manufacture protein therapeutics faster and domestically in the US, targeting the wave of AI-designed biologics and the reshoring of drug manufacturing away from China.
Executive Summary
Bramante Biologics is a pre-seed YC X25 (2025) CDMO startup building modular, AI-driven microfactories for domestic US biologics manufacturing — a thesis with genuine macro tailwinds from the BIOSECURE Act, US reshoring policy, and the emerging wave of AI-designed protein therapeutics. The market opportunity is real and well-timed, and the founding team has complementary skills with directly relevant prior biomanufacturing startup experience. However, at just 2 employees and ~$500K raised, Bramante faces a brutal capital gap: building even a minimal GMP-compliant biologics facility typically costs $50M–$200M, and incumbent CDMOs like National Resilience, ElevateBio, and Fujifilm Diosynth are already spending billions on the same US reshoring wave. The single biggest risk is not whether the market exists — it does — but whether this team can raise enough capital, hire the right regulatory and manufacturing talent, and reach operational GMP status before well-funded competitors lock up the early client relationships.
Run your own diligence
Upload a pitch deck or paste any company URL to get a full AI-powered due diligence report in under 2 minutes.
Get started free →Free plan available · No credit card required